Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial

Hanem, Liv Guro Engen; Salvesen, Øyvind; Juliusson, Petur B; Carlsen, Sven M; Nossum, Marit Cecilie Fonn; Vaage, Marte Øye; Ødegård, Rønnaug; Vanky, Eszter

doi:10.1016/s2352-4642(18)30385-7

Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial

BACKGROUND Metformin is increasingly used to treat gestational diabetes and type 2 diabetes in pregnancy, and in attempts to improve pregnancy outcomes in polycystic ovary syndrome and obesity. It passes across the placenta with possible long-term consequences for the offspring. We previously exp…